MCK241206C625000
- 3.40
- -0.70-17.07%
McKesson Newsroom
Jefferies Maintains McKesson(MCK.US) With Buy Rating, Raises Target Price to $715
Jefferies Sticks to Its Buy Rating for McKesson (MCK)
Jefferies Raises Price Target on McKesson to $715 From $607
J.P. Morgan Maintains McKesson(MCK.US) With Buy Rating, Raises Target Price to $708
J.P. Morgan Sticks to Their Buy Rating for McKesson (MCK)
McKesson Analyst Ratings
Citi Maintains McKesson(MCK.US) With Buy Rating, Raises Target Price to $713
Analysts Conflicted on These Healthcare Names: McKesson (MCK), Fate Therapeutics (FATE) and Voyager Therapeutics (VYGR)
Barclays Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $668
Evercore Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $680
A Quick Look at Today's Ratings for McKesson(MCK.US), With a Forecast Between $612 to $688
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), McKesson (MCK) and Enhabit, Inc (EHAB)
Mizuho Adjusts Price Target on McKesson to $550 From $530, Maintains Neutral Rating
McKesson Is Maintained at Outperform by Evercore ISI Group
A Quick Look at Today's Ratings for McKesson(MCK.US), With a Forecast Between $535 to $688
McKesson Analyst Ratings
Barclays Remains a Buy on McKesson (MCK)
Analysts Conflicted on These Healthcare Names: Ultragenyx Pharmaceutical (RARE), Henry Schein (HSIC) and McKesson (MCK)
McKesson's Strong Q2 Performance and Upward EPS Guidance Justify Buy Rating
Barclays Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $616